Business profile & competitive position
The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry, best known for a stable of branded cleaning, food, and personal-care products sold to consumers and professional buyers. Its consumer-facing lineup includes Clorox bleach, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while professional sales run under Purell, CloroxPro, and Clorox Healthcare. That brand concentration is the core of its competitive profile: it competes mainly on shelf space, brand recognition, and repeat purchase habits rather than on price alone.
On the numbers, the business earns a positive 9.4% net margin, which is consistent with a mature, branded staples model that has pricing power and recurring demand. The P/E of 19.0 and beta of 0.58 also fit the defensive, lower-volatility profile. The reported ROE of -1920.6%, however, is a glaring outlier. A negative and extremely large ROE does not look like an operating-loss story when net margins are positive; it is usually a capital-structure signal, such as negative or very thin shareholders’ equity on the balance sheet. For Clorox, this likely reflects the combined effect of share buybacks, the GOJO acquisition, and accounting adjustments that have compressed the equity base rather than a collapse in cash generation. Still, it is a reminder that the equity cushion here is thin, and that reported earnings need to be weighed against the balance-sheet structure.
Financial posture
Clorox carries a $12.8 billion market capitalization and trades at a 19.0x price-to-earnings multiple at the current price of $105.53. That valuation sits in the middle of the historical range for large-cap household-products companies—not deep value, but not aggressively expensive on headline earnings either. The 9.4% net margin supports the idea that the underlying operations still generate profit out of each dollar of sales, and the 0.58 beta tells investors the stock has historically moved about half as much as the overall market, which is what one would expect from a defensive staples name.
The main nuance is the balance-sheet distortion captured in the -1920.6% ROE. When profitability metrics are dominated by leverage, the stock’s “staples” safety label becomes conditional on cash flows remaining stable enough to service the capital structure. In short, the financial posture is one of a steady-margin consumer franchise that is carrying a non-trivial amount of financial engineering risk alongside its brand equity.
Strategic priorities & outlook
According to the company’s most recent 10-K, Clorox describes itself as a multinational manufacturer and marketer with fiscal 2026 net sales of roughly $6.7 billion, about 9,200 employees, operations in approximately 25 countries, and sales into about 95 markets. Its stated strategy is the IGNITE framework, built around four choices: fuel long-term profitable growth, innovate consumer experiences, reimagine how the company and its people work, and continuously evolve the product portfolio.
Operationally, management is focused on three near-term levers. The first is the completion and optimization of a new enterprise resource planning (ERP) system and a broader digital transformation, aimed at supply-chain efficiencies, digital commerce, innovation, and brand-building. The second is investment in strong brands, strategic digital capabilities, and a streamlined operating model to build resilience and deliver consistent profitable growth. The third is advancing the health and hygiene expansion, especially integrating the April 2026 acquisition of GOJO Industries, which adds Purell and broadens the business-to-business presence.
The 10-K also flags real headwinds. Fiscal 2026 organic sales and earnings both declined, with diluted EPS down 26%. Part of that drop was attributed to macroeconomic headwinds, and part to ERP transition timing that had pulled some sales forward into fiscal 2025. Customer concentration is another operational fact: Walmart alone accounted for 26% of consolidated fiscal 2026 net sales, and the five largest customers represented about half of consolidated net sales. Separately, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, and Clorox purchased P&G’s 20% interest in the venture; Glad retained core intellectual-property licenses on a royalty-free basis.
Macro & geopolitical exposure
As a Consumer Defensive / Household & Personal Products company, Clorox sits in a sector that is usually recession-resistant but not macro-immune. Because cleaning, food, and pet products are everyday purchases, volume tends to hold up when discretionary spending weakens. The main external exposures are input costs, retail concentration, regulation, trade, and currency.
Raw materials matter. Plastics and petrochemical-based packaging, resins, surfactants, paper pulp, and transportation fuel all feed into Clorox’s cost structure. When commodity prices rise or supply chains tighten, margin pressure can follow, even if the company ultimately passes some of those costs through to retailers. Regulatory exposure is also inherent: disinfectant claims fall under EPA oversight, while personal-care products such as Burt’s Bees face FDA and state-level cosmetic regulations. Currency risk is real because the company sells into roughly 95 markets; a stronger U.S. dollar reduces the translated value of overseas revenue. Trade policy and tariffs matter mainly through imported raw materials and packaging, not through a heavy direct-exporter profile. Finally, the high share of sales concentrated at Walmart and other large retailers gives those customers significant bargaining leverage over pricing, promotion, and shelf placement.
Recent developments
The most recent news coverage around Clorox has been defensive and income-oriented. On November 9, 2026, fool.com included Clorox in a piece titled “3 Magnificent High-Yield Dividend Stocks to Buy Near Their 52-Week Lows,” and the same day benzinga.com noted Clorox alongside Take-Two, ExxonMobil, and a financial stock in its recap of CNBC’s “Final Trades.” On November 6, 2026, defenseworld.net published a comparison of Clorox and Reynolds Consumer Products, and on November 5, 2026, fool.com featured Clorox in “3 High-Yielding Dividend Stocks That Investors Can Safely Buy and Hold for Decades.” This cluster of headlines suggests the market is currently framing the stock as a high-yield, defensive, long-duration holding rather than a growth or turnaround story.
Earnings behavior & post-earnings drift
Clorox has beaten earnings expectations in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 11.1%. Across those same quarters, the average 5-day price move after the report has been 7.03% to the upside, classifying the post-earnings drift as “up.” That combination—a high beat rate and a positive average drift—suggests that the stock has often delivered better-than-expected results that the market has rewarded over the following week.
The last four quarters show the nuance behind the averages. On November 2, 2026, Clorox reported actual EPS of $1.55 versus an estimate of $1.07, a 44.9% surprise; the stock rose 4.34% the next day and 17.39% over the following five days. On August 3, 2026, EPS of $1.66 beat the $1.64 estimate by 1.2%, and the stock gained 6.52% the next day and 9.61% over the next five days. On April 30, 2026, EPS of $1.64 beat the $1.55 estimate by 5.8%, yet the stock fell 9.67% the next day and 4.49% over the next five days—a clear example where the headline beat was lower than the market’s real expectation or where guidance overshadowed the print. On February 3, 2026, EPS of $1.39 missed the $1.43 estimate by 2.8%, but the stock still rose 2.43% the next day and 5.63% over five days, implying bad news was already priced in.
Clorox next reports on February 2, 2027, after the market close, with a consensus EPS estimate of $1.07. At the current price of $105.53, the stock is also technically extended, with an RSI of 79.4 and a 50-day EMA of $90.61.
Frequently Asked Questions
Why is Clorox’s ROE reported as negative?
The reported ROE of -1920.6% is an extreme accounting ratio. Because Clorox also has a positive 9.4% net margin and a P/E of 19.0, the distortion is most likely driven by a very low or negative shareholders’ equity base from acquisitions, share buybacks, and balance-sheet restructuring rather than from operating losses.
What are Clorox’s main strategic priorities?
Clorox’s IGNITE strategy focuses on four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and people work, and evolving the product portfolio. Near-term priorities include completing a new ERP system, integrating the April 2026 GOJO acquisition, expanding health and hygiene, and streamlining the operating model. Fiscal 2026 net sales were about $6.7 billion, but diluted EPS fell 26%.
How has CLX historically moved around earnings?
Over the last eight quarters, Clorox has beaten estimates 75% of the time with an average earnings surprise of 11.1%, and the average 5-day post-earnings drift has been 7.03% higher. However, the reaction is not uniform: the November 2, 2026 beat drove a 17.39% five-day gain, while the April 30, 2026 beat was followed by a 9.67% one-day drop.
For a deeper look at how the sell side is modeling margins, leverage, and the GOJO integration, see the full institutional verdict on the company page.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-11-02 | $1.55 | $1.07 | +44.9% | +4.34% | +17.39% |
| 2026-08-03 | $1.66 | $1.64 | +1.2% | +6.52% | +9.61% |
| 2026-04-30 | $1.64 | $1.55 | +5.8% | -9.67% | -4.49% |
| 2026-02-03 | $1.39 | $1.43 | -2.8% | +2.43% | +5.63% |
| 2025-11-03 | $0.85 | $0.818 | +3.9% | - | - |
| 2025-07-31 | $2.87 | $2.2 | +30.5% | - | - |
Previous CLX editions
Get the institutional verdict on CLX
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the CLX verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.